Fingerprint
Dive into the research topics of 'Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
Philippe Armand*, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P. Leonard, Scott J. Rodig, Patricia Martín-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M. Ansell
*Corresponding author for this work
- Dana-Farber Cancer Institute
- University Hospital Gasthuisberg
- ASST Papa Giovanni XXIII
- University of California, Los Angeles (UCLA)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
- Hospital Universitari de Bellvitge
- The Royal Marsden NHS Foundation Trust
- Cornell University
- New York-Presbyterian Hospital
- Brigham and Womens Hospital
- Mayo Clinic (HQ)
- Bristol-Myers Squibb Company
Research output: Contribution to journal › Article › peer-review